Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence

Authors: Carls GS, Tan R, Zhu JY, Tuttle E, Yee J, Edelman SV, Polonsky WH.

Abstract

Aims: The study aims to examine real-world weight change and the role of medication adherence among patients with type 2 diabetes who initiated one of three drug classes: glucagon-like peptide-1 receptor agonist (GLP-1RA), dipeptidyl peptidase-4 inhibitor (DPP4) and sulfonylureas (SUs).

Materials and methods: A cohort of patients initiating one of the three drug classes was selected from a large US database of integrated electronic medical record and administrative claims. Adherence was defined as per cent of days covered ≥80% during the year following drug initiation. Weight change was calculated from drug initiation (-180, +30 d) to 1 year (±90 d) later. Multivariate regression controlled for baseline differences between adherent and poorly adherent patients and the addition of another drug class during follow-up.

Results: The study included 833 GLP-1RA, 2,272 DPP4 and 2,713 SU patients who contributed 2,279, 6,602 and 7,429 observations respectively. Patients initiating a GLP-1RA achieved the largest weight change (-2.46 kg of GLP-1RA, -1.26 kg of DPP4 and 0.18 kg of SU, P < 0.01). Adherent GLP-1 patients lost 1.73 kg more than poorly adherent patients, and adherent SU patients gained 1.11 kg more than poorly adherent patients (all P < 0.01). Adherent and poorly adherent DPP4 patients experienced approximately the same amount of weight loss.

Conclusions: Medication adherence can mediate observed weight loss in patients treated with a GLP1-RA or weight gain in those treated with an SU. Medication adherence was low in a real-world population, particularly for GLP-1RA, which displayed the strongest weight loss benefit. Because recent American Diabetes Association guidelines recommend selecting drug therapies that have a weight loss or weight neutral effect for the management of type 2 diabetes patients, patients should be encouraged to enhance their adherence to benefit the most from therapies that have weight loss properties.

Source: https://pubmed.ncbi.nlm.nih.gov/29071110/

Share the Post:

BDI Monthly Events

November 11
November 11Case Consultation
November 11: BDI hosts the San Diego-wide, monthly case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at info@behavioraldiabetes.org if you are in the greater San Diego area and would like further information about this program.
November 14
November 14World Diabetes Day!
November 14: World Diabetes Day! Time for another T1D meet-up! GrownupT1Ds, a wonderful nonprofit that organizes fun social events for adults with type 1 diabetes here in southern California and now spreading to other cities across the United States. The next local one will be at Brewery X, 3191 E. La Palma Ave., Anaheim, CA 92806. Things get started at 2:00 P.M. Please RSVP at kelly@grownup.t1ds.org
November 26
November 26Happy Thanksgiving!
This Thanksgiving, we are especially grateful for the individuals, families, healthcare professionals, and friends who make up the BDI community. Thank you for your continued support and for sharing in our mission to improve the emotional well-being of people living with diabetes. Wishing you and your loved ones a warm and happy Thanksgiving!
November 3
November 3Engaging the Disengaged
November 3: Dr. Polonsky (BDI President) will be speaking on “Engaging the Disengaged: Diabetes Distress, Diabetes Burnout and More” at the Southern California Permanente Medical Group’s 32th Annual Diabetes Hybrid Symposium, in Long Beach (CA).